Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Cash & Equivalents (2023 - 2025)

Beta Bionics (BBNX) has disclosed Cash & Equivalents for 3 consecutive years, with $31.6 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 3.76% to $31.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.6 million through Dec 2025, up 3.76% year-over-year, with the annual reading at $31.6 million for FY2025, 3.76% up from the prior year.
  • Cash & Equivalents hit $31.6 million in Q4 2025 for Beta Bionics, down from $38.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $42.5 million in Q1 2025 to a low of $13.0 million in Q2 2024.
  • Historically, Cash & Equivalents has averaged $28.6 million across 3 years, with a median of $30.4 million in 2024.
  • Biggest YoY gain for Cash & Equivalents was 169.21% in 2025; the steepest drop was 3.76% in 2025.
  • Year by year, Cash & Equivalents stood at $26.6 million in 2023, then grew by 14.55% to $30.4 million in 2024, then rose by 3.76% to $31.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for BBNX at $31.6 million in Q4 2025, $38.5 million in Q3 2025, and $35.1 million in Q2 2025.